GlassScriptPhysician profile
Hannah Jordan
NPI 1215507512
$2,204.51
in general payments reported to CMS, 2019-2025
26 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.55 · 2022: $50.69 · 2023: $152 · 2024: $670 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $535.00 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $515.99 | 2023-2025 | |
| Pfizer INC. | $195.54 | 2024-2025 | |
| Novo Nordisk INC | $128.73 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $101.61 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.56 | 2025 | Caplyta |
| Verity Pharmaceuticals INC. | $56.70 | 2024 | Tlando |
| Lilly USA, LLC | $56.01 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $49.63 | 2025 | Otezla, Repatha |
| Organon LLC | $47.21 | 2022-2023 | Nexplanon |
| Lundbeck LLC | $45.29 | 2025 | Vyepti, Rexulti |
| Glaxosmithkline, LLC. | $44.37 | 2022-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $42.24 | 2025 | Symbravo, Auvelity |
| Sumitomo Pharma America, INC. | $37.14 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $36.06 | 2025 | Spravato |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $34.86 | 2025 | |
| Optinose US, INC. | $29.55 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $29.47 | 2024-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $28.28 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $21.34 | 2024 | |
| Biotronik Nro, INC. | $21.09 | 2025 | Prospera |
| Genzyme Corporation | $19.59 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $17.55 | 2021 | |
| Corium, LLC | $15.96 | 2023 | Adlarity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2025 | Jardiance |
| Astellas Pharma US INC | $14.27 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.